Therefore, the correlations of risk scores with the relative expression levels of immune checkpoint inhibitors (PD1, PDL1, and CTLA4) were evaluated to further explore their association with immunotherapy because immune checkpoint inhibitors (ICI) are becoming standard in the first-line treatment of advanced NSCLC (Garon et al., 2015; Reck et al., 2016; Gandhi et al., 2018). This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.